CKD-EPI Equations for Glomerular Filtration Rate (GFR)
Uses serum creatinine, serum cystatin C, or both to estimate GFR.
作成者説明
For use in patients with stable, chronic kidney disease to measure kidney function.
The 2021 CKD-EPI equation is now the recommended standard.
To improve accuracy the combined creatinine and cystatin C equation is preferred. It is also recommended as a confirmatory test in patients with extreme body composition (e.g. malnourished, amputees, obese patients, high or low muscle mass) and special populations, including pregnancy and diabetes, as creatinine-based estimates are less accurate in these contexts.
However, serum cystatin C is not as widely available. The creatinine-based equation is still adequate for many clinical contexts, and is currently recommended for GFR reporting in the United State.
Not for use in patients on dialysis.
Adjustments based on race
The 2021 versions presented here do not include race but the 2009 and the 2012 CKD-EPI creatinine and creatinine-cystatin C versions do include race. However, adjustments base on race appear to be controversial, and the pros/cons of adjustments ought to be part of a shared decision-making approach between the clinician and the patient. For more information on the topic of eGFR equations and race, NephJC (FitzGerald, 2019) provides an excellent primer on the subject.
* Factors in race (Black or Non-black) into GFR estimate.
Introduction
CKD-EPI Equations are the standard used to measure kidney function in patients with stable, chronic kidney disease (not acute). These equations use creatinine or a combination of creatinine and cystatin C to measure creatinine clearance as a proxy to estimate glomerular filtration rate(rate).
The 2021 CKD-EPI creatinine-cystatin C version is the recommended standard and the 2021 CKD-EPI creatinine version is currently recommended by the ASN and NKF for GFR reporting in the United States. However, cystatin C is not available in all laboratories. Yet, the creatinine-based version is adequate for many clinical applications even though the combined creatinine and cystatin C can add accuracy. However, specific populations, such as diabetics, pregnant women, and individuals with unusual body mass (obese, amputees, and severe malnutrition), are at risk for less accurate creatinine-based estimates of kidney function. The 2021 CKD-EPI creatinine-cystatin may offer improved accuracy in these special populations with the addition of cystain C, and is recommended as a confirmatory test in patients with extremes of body composition, to include body fat or muscle mass. CKD-EPI is not indicated for patients on dialysis.
Some of the CKD-EPI equations include adjustments based on race. However, adjustments base on race appear to be controversial and the pros/cons of adjustments ought to be part of a shared decision-making approach between the clinician and the patient. For more information on the topic of eGFR equations and race, NephJC (FitzGerald, 2019) provides an excellent primer on the subject.
The CKD-EPI (creatinine) was developed by Levey et al (2009).
Uses the new gold standard: Clearance of iothalamate
Uses linear regression to estimate the logarithm of measured GFR from standardized creatinine levels, sex, race, and age.
2021 CKD-EPI Creatinine
= 142 x (Scr/A)^B x 0.9938^age x (1.012 if female)
A & B as follows:
Female: |
| Male: |
|
Scr ≤ 0.7 | A= 0.7 | Scr ≤ 0.9 | A= 0.9 |
| B= -0.241 |
| B= -0.302 |
|
|
|
|
Scr > 0.7 | A= 0.7 | Scr > 0.9 | A= 0.9 |
| B= -1.2 |
| B= -1.2 |
2021 CKD-EPI Creatinine-Cystatin C
= 135 x (Scr/A)^B x (Scys/C)^D x 0.9961^age x (0.963 if female)
A, B, C & D as follows:
Female: |
|
|
|
| Male: |
|
|
|
| Scr ≤ 0.7 |
| Scr > 0.7 |
|
| Scr ≤ 0.9 |
| Scr > 0.9 |
Scys ≤ 0.8 | A= 0.7 |
| A= 0.7 |
| Scys ≤ 0.8 | A= 0.9 |
| A= 0.9 |
| B= -0.219 |
| B= -0.544 |
|
| B= -0.144 |
| B= -0.544 |
| C= 0.8 |
| C= 0.8 |
|
| C= 0.8 |
| C= 0.8 |
| D= -0.323 |
| D= -0.323 |
|
| D= -0.323 |
| D= -0.323 |
|
|
|
|
|
|
|
|
|
Scys > 0.8 | A= 0.7 |
| A= 0.7 |
| Scys > 0.8 | A= 0.9 |
| A= 0.9 |
| B= -0.219 |
| B= -0.544 |
|
| B= -0.144 |
| B= -0.544 |
| C= 0.8 |
| C= 0.8 |
|
| C= 0.8 |
| C= 0.8 |
| D= -0.778 |
| D= -0.778 |
|
| D= -0.778 |
| D= -0.778 |
2009 CKD-EPI Creatinine*
= A x (Scr/B)^C x 0.993^Age x (1.159 if black)
A, B & C as follows:
Female: |
| Male: |
|
Scr ≤ 0.7 | A= 144 | Scr ≤ 0.9 | A= 141 |
| B= 0.7 |
| B= 0.9 |
| C= -0.329 |
| C= -0.411 |
|
|
|
|
Scr > 0.7 | A= 144 | Scr > 0.9 | A= 141 |
| B= 0.7 |
| B= 0.9 |
| C= -1.209 |
| C= -1.209 |
2012 CKD-EPI Cystatin C
= 133 x (scys/0.8)^A x 0.996^age x B
A& B as follows:
Female: |
|
| Male: |
Scys ≤ 0.8 | A= -0.499 |
| A= -0.499 |
| B= 0.932 |
| B= 1 |
|
|
|
|
Scys > 0.8 | A= -1.328 |
| A= -1.328 |
| B= 0.932 |
| B= 1 |
2012 CKD-EPI Creatinine-Cystatin C*
= A x (Scr/B)^C x (Scys/0.8)^D x 0.995^age x (1.08 if Black)
A, B, C, & D as follows:
Female: |
|
|
|
| Male: |
|
|
|
| Scr ≤ 0.7 |
| Scr > 0.7 |
|
| Scr ≤ 0.9 |
| Scr > 0.9 |
Scys ≤ 0.8 | A= 130 |
| A=130 |
| Scys ≤ 0.8 | A= 135 |
| A= 135 |
| B= 0.7 |
| B= 0.7 |
|
| B= 0.9 |
| B= 0.9 |
| C= -0.248 |
| C= -0.601 |
|
| C= -0.207 |
| C= -0.601 |
| D= -0.375 |
| D= -0.375 |
|
| D= -0.375 |
| D= -0.375 |
|
|
|
|
|
|
|
|
|
Scys > 0.8 | A= 130 |
| A= 130 |
| Scys > 0.8 | A= 135 |
| A= 135 |
| B= 0.7 |
| B= 0.7 |
|
| B= 0.9 |
| B= 0.9 |
| C= -0.248 |
| C= -0.601 |
|
| C= -0.207 |
| C= -0.601 |
| D= -0.711 |
| D= -0.711 |
|
| D= -0.711 |
| D= -0.711 |
*Race may or may not provide better estimates of GFR. Using the adjustment coefficient for black patients is controversial (Inker et al, 2021) and is an optional component.
Abbreviations
Scr = serum creatinine (mg/dL)
Scys = serum cystatin C (mg/L)
GFR = glomerular filtration rate (ml/min/1.73 m²)
Chronic Kidney Disease (CKD) Staging
GFR Stage | GFR Description | GFR Range |
I | Normal or High | ≥90 |
II | Mildly decreased | 60-89 |
IIIa | Mildly to moderately decreased | 45-59 |
IIIb | Moderately to severely decreased | 30-44 |
IV | Severely decreased | 15-29 |
V | Kidney failure | <15 |
すべての質問と考えられる結果
Instructionsタイトルは非表示です
Equation
* Factors in race (Black or Non-black) into GFR estimate.
Select one option:
- 2021 CKD-EPI Creatinine
- 2021 CKD-EPI Creatinine-Cystatin C
- 2009 CKD-EPI Creatinine*
- 2012 CKD-EPI Cystatin C
- 2012 CKD-EPI Creatinine-Cystatin C*
Sex
Select one option:
- Male
- Female
Age
A number between 0 and 200, in years.
Serum creatinine
A number between 0 and 100, in mg/dL or µmol/L.
Serum cystatin C
A number between 0 and 100, in mg/L.
Race
Optional: Race may or may not provide better estimates of GFR.
Select one option:
- Black
- Non-black
考えられる結果
CKD stage (2012 CKD-EPI Cystatin C)
According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.
CKD stage (2012 CKD-EPI Creatinine-Cystatin C)
According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.
CKD Stage (2021 CKD-EPI Creatinine-Cystatin C)
According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.
CKD stage (2021 CKD-EPI Creatinine)
According to the KDIGO clinical practice guidelines (2012), patients are classified into a CKD stage using both eGFR and albuminuria status. Decreased GFR, increased urinary albumin excretion, or both are considered high risk for progressive kidney disease. Referral to nephrology for further management is indicated for high risk patients.
文献
A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12.
https://pubmed.ncbi.nlm.nih.gov/19414839/Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012 Jul 5;367(1):20-9.
https://pubmed.ncbi.nlm.nih.gov/22762315/New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021 Nov 4;385(19):1737-1749.
https://pubmed.ncbi.nlm.nih.gov/34554658/KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
https://kdigo.org/guidelines/ckd-evaluation-and-management/KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
https://kdigo.org/guidelines/diabetes-ckd/Reconsidering the consequences of using race to estimate kidney function. JAMA. 2019; 322(2):113-114.
https://jamanetwork.com/journals/jama/article-abstract/2735726?guestAccessKey=61504cca-3e81-4423-b608-164f044e9a58&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=080519
- 作成者
Dr. Andrew S. Levey, MDChief of the nephrology division at Tufts Medical Center and the Dr. Gerald J. and Dorothy R. Friedman Professor at Tufts University School of Medicine.
- 作成者
Dr. Lesley A. Inker, MD, MSAssociate professor at Tufts University School of Medicine, an attending physician in the William B. Schwartz, MD Division of Nephrology at Tufts Medical Center, and medical director of the Kidney And Blood Pressure Center at Tufts Medical Center in Massachusetts.
- 作成者Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)Research group with interests in measurement and estimation of GFR (CKD-EPI GFR) and evaluation of surrogate endpoints for clinical trials in CKD (CKD-EPI CT).
- 提供元
EVAL Foundation
- 寄稿者 · 査読者
Jennifer Glen, DNP, FNP-BCEVAL Health, Chief Medical Officer EVAL Foundation